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Similar sequence, different function
During cutaneous inflammation in humans, both hS100A7 
(psoriasin) and hS100A15 are upregulated. Despite a very 
recent evolutionary divergence and an extremely high homo­
logy (93% sequence identity), these proteins not only exhibit 
unique expression but also have distinct functions. Wolf and 
colleagues demonstrated that in vitro hS100A15 was chemot­
actic for granulocytes and monocytes but not for lympho­
cytes, whereas hS100A7 was chemotactic for all three types 
of leukocytes. Another interesting difference between these 
two similar proteins is the receptor involved in chemotaxis: 
hS100A15 signals through a Gi protein–coupled receptor 
(GiPCR), whereas hS100A7 appears to function through the 
receptor for advanced glycation end products. These two pro­
teins are proinflammatory and function synergistically in vivo, 
albeit through unique molecular mechanisms. Understanding 
this diversity coupled with this synergy will undoubtedly facil­
itate the development of therapies for cutaneous inflammatory 
diseases such as psoriasis. (J Immunol 181:1499–506, 2008)
Improved adjuvant for melanoma
IFN­α2b has been shown to reduce the risk of recurrence 
or death in patients with stage IIb and stage III melanoma. 
Because these patients are at high risk for tumor recurrence 
following surgery, effective adjuvant therapy is particularly 
useful. Pegylation of IFN­α2b has been proven safe for use in 
several types of cancer. Eggermont and colleagues recently 
demonstrated that recurrence­free survival was significantly 
improved in patients with stage III melanoma who received 
adjuvant IFN­α2b and that an increase in metastasis­free 
survival was observed, although the difference was not 
statistically significant. The toxicity of this treatment was 
also considered acceptable. Pegylated IFN­α2b may be an 
effective option for adjuvant treatment to reduce the risk of 
relapse and potentially achieve a cure. Although these results 
indicate that patients with low tumor volume and an ulcer­
ated primary tumor may be likely candidates to benefit from 
adjuvant IFN­α2b, this study highlights the importance of con­
firming markers in such patients. (Lancet 372:117–26, 2008)
Direct delivery
Integrin­αvβ3, which is preferentially expressed on angiogen­
ic endothelium in malignant tissues, is an attractive target for 
the delivery of cancer therapeutics via nanoparticles (NPs). 
Previous work indicated that the αv­integrin­targeting pep­
tide RGD­4C was effective at delivering doxorubicin (Dox) 
to tumor neovasculature. Murphy and colleagues then dem­
onstrated that integrin­αvβ3 targeting of Dox­containing NPs 
strongly inhibited angiogenesis. After RGD­Dox­NP treat­
ment in both pancreatic carcinoma and renal cell carcinoma 
models, a modest effect was observed on primary tumor 
growth and a substantial effect was observed on metastatic 
disease. Importantly, a 15­fold improvement in drug efficacy 
was noted when Dox was delivered via this integrin­targeting 
system. Because targeted NP delivery exhibited high effi­
ciency without accompanying side effects, this targeting will 
be a candidate mechanism for the delivery of new pharma­
cological agents designed to suppress tumor or vascular cell 
signaling. (Proc Natl Acad Sci USA 105:9343–8, 2008)
TH17 cells: of mice and men
TH17 cells have been implicated in an array of autoimmune 
disorders, from multiple sclerosis to rheumatoid arthritis and 
psoriasis. In vitro studies on the differentiation of TH17 cells 
have illuminated differences between mice and humans. 
Using a system to independently examine the effects of 
cytokines on memory T cells and naive CD4+ lymphocytes 
from humans, Yang and colleagues demonstrated a require­
ment for IL­21 and transforming growth factor (TGF)­β in dif­
ferentiation of naive CD4+ T cells to TH17 cells. In addition, 
IL­1β and IL­6 induced IL­17A secretion from human memo­
ry CD4+ T cells. Induction of the critical transcription factors 
RORC2 and FOXP3 was similar in mouse and human naive 
CD4 cells; however, induction of IL­17A by IL­6 and TGF­β 
differed between the species. This report more clearly defines 
the conditions required for human TH17­cell differentiation 
and offers insight into future exploration of human inflam­
matory TH17 responses in autoimmune diseases. (Nature 
454:350–2, 2008)
CD19 is critical in systemic sclerosis
Systemic sclerosis (SSc) is a connective tissue disease 
characterized by excessive extracellular matrix deposition, 
abnormal activation of immune cells, elevated serum cytokine 
levels, and the presence of autoantibodies. The recent devel­
opment of a new bleomycin­induced SSc model prompted 
Yoshizaki and colleagues to examine this disease in mice 
deficient for CD19, a critical signal­transduction component 
that regulates humoral immune responses, autoimmunity, and 
cytokine production. Interestingly, CD19 deficiency inhibited 
the development of skin and lung fibrosis and autoantibody 
production following induction of SSc with bleomycin. 
Bleomycin treatment enhanced the production of hyaluronan, 
a Toll­like receptor (TLR2 and TLR4) ligand that stimulated B 
cells to generate cytokines. In the absence of CD19, however, 
this bleomycin­induced cytokine production was suppressed. 
Importantly, the reduced fibrosis in the CD19­deficient mice 
was accompanied by decreased infiltration of immune cells, 
and thus the authors asserted the importance of B­cell activa­
tion for downstream inflammation and autoimmune response 
in SSc. (Am J Pathol 172:1650–63, 2008)
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